{
    "title": "114_s2994",
    "content": "The \"DXM Abuse Prevention Act of 2016\" requires retailers to implement a verification system for sales of over-the-counter drugs containing dextromethorphan. Failure to do so is considered a prohibited act under the Federal Food, Drug, and Cosmetic Act. Retailers selling dextromethorphan in interstate commerce must have a verification system in place to ensure compliance with age restrictions. This system can include electronic point-of-sale prompts, employee training, signage, designated approval personnel, or other approved verification measures. Retailers must verify the age of individuals purchasing dextromethorphan, except for those over 26, with a valid prescription, or with a valid military identification card. Retailers must verify the age of individuals buying dextromethorphan, except for those over 26, with a valid prescription, or with a valid military ID card. An affirmative defense is available if the seller checked the buyer's ID and reasonably determined they were at least 18 years old. The ID must have a photo, date of birth, and be issued by a State or the Federal Government. Civil penalties for violations of section 301(eee) under the Federal Food, Drug, and Cosmetic Act include receiving a violation notification for the first offense and escalating civil penalties for subsequent violations. The penalties amount to $1,000 for the second violation and $2,000 for the third violation by an individual. The civil penalties for violations of section 301(eee) under the Federal Food, Drug, and Cosmetic Act include escalating fines for repeat offenses, with penalties of up to $5,000 for the fourth violation by a person. Retailers can mitigate penalties by implementing employee training programs on dextromethorphan products and ID checks. The civil penalties for violations of section 301(eee) under the Federal Food, Drug, and Cosmetic Act include escalating fines for repeat offenses, with penalties of up to $5,000 for the fourth violation by a person. Retailers can mitigate penalties by implementing employee training programs on dextromethorphan products and ID checks. Retailers transacting sales of products containing dextromethorphan at multiple locations will be considered separate entities for violation purposes. The Secretary will promptly notify violators and provide details of the observed violation. Employees are prohibited from violating the regulations. Employees in clerical or non-managerial positions at retailers like grocery stores or pharmacies are not penalized under section 301(eee) unless they knowingly participate in a conspiracy to violate the section. A conspiracy involves an agreement between two or more individuals to violate the section and the commission of at least one overt act in furtherance of the agreement. Activities as a distributor involving products with dextromethorphan are primarily limited to personal use sales, including online sales. SEC. 3. RESTRICTIONS ON DISTRIBUTION OF BULK DEXTROMETHORPHAN. The Federal Food, Drug, and Cosmetic Act is amended to include restrictions on the distribution of bulk dextromethorphan. No person can possess or receive unfinished dextromethorphan unless registered under relevant laws for pharmacy or drug distribution. Distribution of unfinished dextromethorphan is restricted to registered individuals. Common carriers are exempt from these restrictions. The section defines terms like common carrier and unfinished dextromethorphan, and outlines restrictions on distributing unfinished dextromethorphan to registered individuals. A person who violates section 506H may face a civil penalty of up to $100,000."
}